Current concepts and future directions in the battle against obesity

Niravel, Aneesa; Smolar, Edward N.

doi:10.1007/s12019-004-0014-2

Cited by 1 publication

(1 citation statement)

References 73 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Yearly, an estimated 300,000 deaths are directly due to being overweight or obese. In one study, it was estimated that overweight individuals have a decreased life expectancy of 3 years, while obese individuals have a life expectancy deficit of 7.1 years for females and 5.8 years for males [4].…”

Section: Introductionmentioning

confidence: 99%

Pharmacological Screening of Anti-Obesity Potential of Acorus Calamus Linn. In High Fat Cafeteria Diet Fed Obese Rats

Athesh¹,

Joshi²

2017

Asian J Pharm Clin Res

View full text Add to dashboard Cite

Objective: To study the anti-obesity potential of aqueous rhizome extract of Acorus calamus Linn. (AREAC) in high-fat diet (HFD) fed obese rats.Methods: Adult strain male Wistar rats used in this study were fed with HFD for 60 days. For the treatment groups, AREAC was administered in a dose levels of 100, 200, and 300 mg/kg bw, orally once a day along with HFD. Rats fed with normal pellet chow were served as normal control. The effect of AREAC on physical parameters such as body weight, organ weight, fat pad weights, and various biochemical parameters such as serum glucose, insulin, leptin, lipid profile, liver markers, kidney markers, and oxidative stress markers were analyzed. In vitro pancreatic lipase inhibition assay of AREAC was also studied.Results: Data of in vivo studies revealed significant (p<0.05) reduction in percentage body weight gain, organ weights, fat pad weights and levels of serum glucose, insulin, and leptin after treatment with AREAC in a dose-dependent manner. Furthermore, administration of AREAC significantly inhibited the increases in the concentrations of triglycerides, total cholesterol, low-density lipoprotein-cholesterol, very low-density lipoproteincholesterol, free fatty acid, and phospholipids in a dose dependent manner whereas, the level of high-density lipoprotein-cholesterol was found to be elevated on treatment. Moreover, on treatment with a test drug, the elevated levels of serum liver and kidney markers such as aspartate transaminase, alanine transaminase, alkaline phosphatase, urea, and creatinine were also brought back to near normalcy. Antioxidant status was found to be enhanced in liver tissues after treatment. In vitro studies showed significant inhibition in the activity of pancreatic lipase by AREAC. Conclusion:The data of the results obtained clearly depicted that AREAC was found to have pronounced anti-obesity activity particularly at the dose levels of 300 mg/kg bw.

show abstract

Section: Introductionmentioning

confidence: 99%